Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

INCLUSION CRITERIA * Histologically-confirmed pancreatic neuroendocrine tumors that are moderately- or well-differentiated * Metastatic or unresectable disease * If prior surgical resection \> 5 years before the development of metastatic disease, a separate (recent) histological or cytological confirmation of metastatic disease is required * If there is substantial clinical ambiguity regarding the nature or source of apparent metastases, clinicians should consider biopsy of lesions to establish diagnosis of metastatic disease * The site of previous radiotherapy, if the only site of disease, has evidence of progressive disease * If prior sunitinib and everolimus has been administered, a 2-week wash-out period is required prior to 1st dose on this study * If prior liver-directed therapies (ie, chemoembolization, radioembolization), target lesions in the liver have demonstrated growth since the liver-directed treatment * If prior peptide receptor radionuclide therapy (PRRT), target lesions in the liver have demonstrated growth since the liver-directed treatment * Low-dose aspirin (≤ 325 mg/d) may be continued in subjects at higher risk for arterial thromboembolic disease. * Primary or metastatic tumor lesion measurable in at least 1 dimension, within 4 weeks prior to entry of study. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * ≥ 18 years of age. * Laboratory values as follows, ≤ 2 weeks prior to randomization: * Absolute neutrophil count (ANC) ≥ 1.…